{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:43:28Z","timestamp":1787013808064,"version":"build-2736575974"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first\u2010line treatment for patients with unresectable MPM. Recently, promising outcomes were observed with first\u2010line bevacizumab combined with cisplatin\/pemetrexed, leading to the recommendation of this regimen as a first\u2010line treatment option for patients with MPM. Bevacizumab plus cisplatin\/pemetrexed has been shown to be safe and effective in non\u2013small cell lung cancer, however, there are no efficacy or safety data in Japanese patients with MPM treated with this regimen. We conducted a multicenter study to evaluate tolerability and safety for Japanese patients with chemotherapy\u2010na\u00efve, unresectable MPM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eligible patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a07) received bevacizumab plus cisplatin\/pemetrexed (up to six\u00a0cycles), then single\u2010agent bevacizumab until disease progression or onset of unacceptable adverse events (AEs), according to the 3+3 design analogy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One patient (14.3%) reported an AE (gastric ulcer) meeting tolerability criteria. All patients experienced gastrointestinal disorders, including nausea (grade 1\/2 only,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a06, 85.7%) and constipation (grade 1\/2 only,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a05, 71.4%). Five patients (71.4%) had grade 3 hypertension. Two patients discontinued treatment due to gastric ulcer (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a01) and proteinuria (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a01). At data cut\u2010off, four patients had stable disease, two had partial response and one had non\u2010complete response\/non\u2010progressive disease due to the absence of target lesions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bevacizumab plus cisplatin\/pemetrexed then bevacizumab was well tolerated in Japanese patients with MPM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.13455","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T12:49:51Z","timestamp":1601038191000},"page":"264-272","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bevacizumab plus cisplatin\/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-1051","authenticated-orcid":false,"given":"Takashi","family":"Nakano","sequence":"first","affiliation":[{"name":"Center for Respiratory Medicine Otemae Hospital  Osaka Japan"},{"name":"Division of Respiratory Medicine Department of Internal Medicine Hyogo College of Medicine  Nishinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine Department of Internal Medicine Hyogo College of Medicine  Nishinomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Morise","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Respirology Chiba University  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Hyogo Prefectural Amagasaki General Medical Center  Amagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiko","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Hirabayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Hyogo Prefectural Amagasaki General Medical Center  Amagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"Zandwijk N","year":"2013","journal-title":"J Thorac Dis"},{"key":"e_1_2_9_3_1","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner JC","year":"1960","journal-title":"Br J Ind Med"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/oemed-2017-104298"},{"key":"e_1_2_9_5_1","unstructured":"Ministry of Health Labour and Welfare Japan.Vital statistics in Japan. 2017.https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/tokusyu\/chuuhisyu17\/dl\/chuuhisyu.pdf(in Japanese). Accessed June 14 2019."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2017.04.09"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3190"},{"key":"e_1_2_9_9_1","unstructured":"National Comprehensive Cancer Network.Malignant Pleural Mesothelioma (Version 2.2019).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf. Accessed June 14 2019."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.824"},{"key":"e_1_2_9_11_1","first-page":"2063","article-title":"Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma","volume":"18","author":"Linder C","year":"1998","journal-title":"Anticancer Res"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.10.010"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181d2f008"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690650"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2005.09.008"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0501"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.9847"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5869"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.08.001"},{"key":"e_1_2_9_24_1","unstructured":"Ministry of Health Labour and Welfare Japan.Notification No. 1101001 (2005)https:\/\/www.pmda.go.jp\/files\/000206740.pdf(in Japanese). Accessed May 29 2019."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3086"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw143"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604442"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.07.003"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.05.111"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.9012"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30139-0"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.05.021"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.05.001"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.003"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13455","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T10:57:30Z","timestamp":1692269850000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/ajco.13455"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13455","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"2019-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}